## **AvMed**

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-305-671-0200</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

NON-PREFERRED

**<u>Drug Requested</u>**: Repository Corticotropin Medications - INFANTILE SPASMS (IS)

**PREFERRED** 

provided or request may be denied.

□ Purified Cortrophin <sup>™</sup> Gel (repository corticotropin)	☐ HP Acthar® Gel (repository corticotropin)  *Member must have tried and failed preferred Purified Cortrophin™ Gel and meet all applicable PA criteria below		
**Acthar Gel single-dose pre-filled SelfJect injector i	is for subcutaneous administration by adults only.**		
MEMBER & PRESCRIBER INFORMATION	<b>ON:</b> Authorization may be delayed if incomplete.		
Member Name:			
Member Sentara #:			
Prescriber Name:			
Prescriber Signature:	Date:		
Office Contact Name:			
Phone Number:	Fax Number:		
NPI #:			
DRUG INFORMATION: Authorization may be	delayed if incomplete.		
Drug Name/Form/Strength:			
Dosing Schedule:	Length of Therapy:		
Diagnosis:	ICD Code, if applicable:		
Weight (if applicable):	Date weight obtained:		
Note: (Neurology 2012;78:1974-1976) Class I study sland high dose (150 IU/m²) natural ACTH. Low dose dose ACTH for treatment of infantile spasms. (Level	ACTH should be considered as an alternative to high		
CLINICAL CRITERIA: Check below all that ap support each line checked, all documentation, including			

(Continued on next page)

171 Repository Corticotropin-15 (11)	wicu,
(Continued from previous	page)

- ☐ Prescriber MUST be a Neurologist
- ☐ Member MUST have a documented diagnosis of Infantile Spasms
- ☐ Approval will only be granted for a MAXIMUM of 30 days only due to similar adverse effects of corticosteroids. After 2 weeks of treatment, dosing should be gradually tapered and discontinued over a 2-week period. The following is one **suggested** tapering schedule:
  - 30 U/m<sup>2</sup> in the morning for 3 days; 15 U/m<sup>2</sup> in the morning for 3 days; 10 U/m<sup>2</sup> in the morning for 3 days; and 10 U/m<sup>2</sup> every other morning for 6 days.
- □ Complete the regimen below (repository corticotropin is supplied as 5 mL multi-dose vial containing 80 USP Units per mL):

Approval will be a MAXIMUM of 30 days only (combined inpatient and outpatient time period)

Initial Dose Schedule		Approval at Outpatient pharmacy will be based on volume needed at discharge from hospital				
75 U/m <sup>2</sup> <b>BID</b> x	days	TOTAL	mL	. X	# days (max 2	29 days)
Taper Dose Schedule			BODY SURFACE AREA BSA			
30 U/m <sup>2</sup> <b>QD</b> x	days	mL x	days	Weight:		kg
15 U/m <sup>2</sup> <b>QD</b> x	days	mL x	days	Height/L	ength:	in.
10 U/m <sup>2</sup> <b>QD</b> x	days	mL x	days	Calculate	ed BSA:	$m^2$
10 U/m <sup>2</sup> <b>QOD</b> x	days	mL x	days			

<b>TOTAL Number of vials needed:</b>	/days	(max 29 d	lays

## Medication being provided by Specialty Pharmacy – Proprium Rx

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

\*\*Use of samples to initiate therapy does not meet step edit/preauthorization criteria. \*\*

\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\*

<sup>\*</sup>Approved by Pharmacy and Therapeutics Committee: 2/21/2008; 9/26/2024 UPDATED/REVISED/REFORMATTED: 1/9/2020; 6/16/2022:10/26/2023: 10/15/2024